IAS 2013: Second-line HIV Therapy with NRTIs Linked to Bone Loss [VIDEO]
- Details
- Category: Bone Loss
- Published on Sunday, 07 July 2013 00:00
- Written by Gregory Fowler
Bone loss occurs less often when people on failing antiretroviral therapy switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Switch to Etravirine Maintains Viral Suppression and Improves Lipid Levels
- Details
- Category: HIV Treatment
- Published on Saturday, 06 July 2013 00:00
- Written by Liz Highleyman
People with HIV who switch from their current antiretroviral regimen to the NNRTI etravirine (Intelence) maintain undetectable viral load and may see improvement in metabolic parameters, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Long-acting GSK1265744 and TMC278-LA Appear Safe and Practical in Early Study
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 05 July 2013 00:00
- Written by Liz Highleyman
A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
Coverage of the 2013 International AIDS Society Conference
- Details
- Category: HIV Treatment
- Published on Saturday, 06 July 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.
Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.
HIVandHepatitis.com IAS 2013 conference section
7/6/13
IAS 2013: First-line Antiretroviral Therapy has Improved Over Time, Meta-analysis Shows
- Details
- Category: HIV Treatment
- Published on Thursday, 04 July 2013 00:00
- Written by Liz Highleyman
The effectiveness of initial antiretroviral treatment has improved markedly over the years, but many people still do not achieve full HIV suppression and a majority end up going off their initial regimen for various reasons, according to a large meta-analysis presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
More Articles...
- IAS 2013: Stem Cell Transplant Patients Remain HIV-Free [VIDEO]
- IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries
- IAS 2013: Boston Stem Cell Transplant Recipients Now Controlling HIV Off Treatment
- IAS 2013: Hepatitis C Reinfection Occurs Frequently Among Gay Men Living with HIV in London
Web Design and Development by